drugset / Trial / NCT05878288
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Phase 2
Active not recruiting
11 enrolled
Peter MacCallum Cancer Centre, Australia
Monash University · collabRegeneron Pharmaceuticals · collabSanofi · collabUniversity of Adelaide · collabUniversity of Melbourne · collab
NaSingle-groupOpen-labelOther
Summary
To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.
Timeline
- Start
- 2023-05-26
- Primary completion
- 2029-05
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |